Accéder au contenu
Merck

A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.

Oncotarget (2015-01-13)
Fengfei Wang, Marc Remke, Kruttika Bhat, Eric T Wong, Shuang Zhou, Vijay Ramaswamy, Adrian Dubuc, Ekokobe Fonkem, Saeed Salem, Hongbing Zhang, Tze-Chen Hsieh, Stephen T O'Rourke, Lizi Wu, David W Li, Cynthia Hawkins, Isaac S Kohane, Joseph M Wu, Min Wu, Michael D Taylor, Erxi Wu
RÉSUMÉ

Over-expression of PDGF receptors (PDGFRs) has been previously implicated in high-risk medulloblastoma (MB) pathogenesis. However, the exact biological functions of PDGFRα and PDGFRβ signaling in MB biology remain poorly understood. Here, we report the subgroup specific expression of PDGFRα and PDGFRβ and their associated biological pathways in MB tumors. c-MYC, a downstream target of PDGFRβ but not PDGFRα, is involved in PDGFRβ signaling associated with cell proliferation, cell death, and invasion. Concurrent inhibition of PDGFRβ and c-MYC blocks MB cell proliferation and migration synergistically. Integrated analysis of miRNA and miRNA targets regulated by both PDGFRβ and c-MYC reveals that increased expression of JAG2, a target of miR-1280, is associated with high metastatic dissemination at diagnosis and a poor outcome in MB patients. Our study may resolve the controversy on the role of PDGFRs in MB and unveils JAG2 as a key downstream effector of a PDGFRβ-driven signaling cascade and a potential therapeutic target.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
10058-F4, ≥98% (HPLC), solid
Sigma-Aldrich
MISSION® esiRNA, targeting human MYC
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Myc
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Nol3
Sigma-Aldrich
MISSION® esiRNA, targeting human NOL3
Sigma-Aldrich
MISSION® esiRNA, targeting human JAG2
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Jag2
Sigma-Aldrich
MISSION® esiRNA, targeting human PDGFRB